Why the CogState share price is surging higher today

The CogState Limited (ASX: CGS) share price surged after the brain health testing company reported a record level of sales contracts.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CogState Limited (ASX: CGS) share price surged after the brain health testing company reported a record level of sales contracts.

The CGS share price jumped 30% to 39 cents during lunch time trade when the All Ordinaries (Index:^AORD) (ASX:XAO) and the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) indices slipped 0.2%.

Healthcare stocks have been big winners in 2019. You only need to look at how the Nanosonics Ltd. (ASX: NAN) and Polynovo Ltd (ASX: PNV) share prices have performed this year to see what I mean.

Turnaround in sentiment

Cogstate isn't quite in the same category of 2019 winners as its share price tumbled by over 30% since January 2019, although today's announcement will help the company make up lost ground.

Management reported that it executed another $19.1 million of clinical trial sales contracts since the start of October. This is on top of the $7.7 million in contracts it achieved in the September quarter.

Record result

The means Cogstate achieved its best first half result on record with the total value of contracts executed since the start of FY20 (meaning July 1) hitting $26.8 million.

The December quarter sales figure is also the highest in at least three years and is better than what the company was expecting a few months ago.

"The level of sales contracts executed in this December half year is a reflection of accelerating demand for the Company's scientific solutions and technologies," said Cogstate chief executive, Brad O'Connor.

"Over the last month especially, we have executed a number of contracts in respect of studies that are planning to begin in the March quarter of 2020."

Beating guidance

Cogstate provided guidance for a 50% increase in clinical trials sales contracts at the start of the financial year. This implies a $27 million sales figure for FY20.

Given we are not even in the second half of the current financial year, Cogstate should easily surpass its guidance.

"The result certainly validates the expectation of a strong rebound from what was a very disappointing 2019 financial year," added O'Connor.

"Cogstate has seen continued sales growth in rare disease indications as well as a rebound in investment by our customers in Alzheimer's disease, an area that was negatively impacted throughout the 2019 financial year by a series of clinical trial failures."

Management will provide a further trading update when it releases its first half results in February next year.

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »